Navigation Links
Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
Date:11/9/2010

esponse and was well tolerated. Vaccine-related serious side-effects which would raise any safety concern were not observed. The results provide a strong basis for evaluation of further development options. Intercell and its partner Novartis will determine next steps.

Clostridium difficile program planned to enter clinic: After successful pre-clinical trials, Intercell is progressing its vaccine candidate to prevent infections with Clostridium difficile (C. diff). C. diff is the leading cause for nosocomial Diarrhea in Europe and the U.S. A Phase I clinical study is expected to start in 2010.

Staphylococcus aureus vaccine (V710) on track: The Phase II/III study conducted and funded by Merck & Co., Inc. in cardiothoracic surgery patients for the investigational S. aureus vaccine is progressing to plan. The first critical interim analysis (surpassing futility) is expected in 2011.

Good progress in development pipeline – programs progressing according to plan

  • Recruitment for the pivotal Phase III study of approximately 2,000 travelers for Intercell's investigational Travelers' Diarrhea (TD) Vaccine Patch is completed. The first data from that trial, conducted in travelers to Mexico and Guatemala, is expected for end 2010/early 2011. The enrollment of a complementary 800-traveler Phase II study in those travelling to India has also been completed; first data is expected in Q4 2010. The trial in India is the first study outside South America and has the potential to demonstrate proof of concept for the vaccine in Asia.
  • Intercell will pursue activities with GSK to prepare markets as soon as data on Phase II and Phase III trials becomes available. Diarrhea is the most common health problem among travelers from developed countries who visit developing areas and most of the diarrheal cases in travelers are caused by bacteria, primarily by ETEC strains (Escherichia coli).
  • Intercell and GSK will continue de
    '/>"/>

  • SOURCE Intercell AG
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections
    2. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
    3. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
    4. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
    5. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
    6. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
    7. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
    8. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
    9. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
    10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
    11. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
    (Date:12/24/2014)... 24, 2014 LifeScienceIndustryResearch.com ... Disposable Syringe Industry of 178 pages providing ... intelligence library. The 2014 Market ... is a professional and deep research report ... analysis, the report introduces Disposable Syringe basic ...
    (Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
    Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
    ... 2011 The CAQH® Universal Provider Datasource® (UPD®) ... as the go-to resource for complete and reliable ...  Three out of five licensed and practicing physicians ... service. About 7,000 additional providers are registering each ...
    ... 2011 Instrumentation Laboratory (IL) today announced the appointment ... effective May 1, 2011.  Mr. Benet began his career ... Vice President of Worldwide Marketing, Sales and Service.   ... Josep Manent who served as CEO since 1999.  Under ...
    Cached Medicine Technology:900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 2900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource 3Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer 2
    (Date:12/24/2014)... 24, 2014 Verde Pointe Dental Associates 2014 ... "Last years homemade Christmas sweater lit up, but this ... 2014 winner is Tandy Wilson for the second year in ... says Kirk Kimmerling DDS. "She took pictures of the entire ... sweater." , "Every year I enjoy stopping by ...
    (Date:12/24/2014)... “ Relax Melodies ” was featured on NewsWatch ... latest and coolest mobile applications on the iOS, Android, ... and host of NewsWatch, conducted the app review and ... they can fall asleep. , According to the National ... some sort of difficulty sleeping. Since that’s a huge ...
    (Date:12/24/2014)... California (PRWEB) December 24, 2014 Final ... of the ProDenoise from Pixel Film Studios. , “The ProDenoise ... or grain in their footage,” said Christina Austin, CEO of ... in any Final Cut Pro X editors toolbox.” , Final ... noise or grain in their footage with ProDenoise from Pixel ...
    (Date:12/24/2014)... Kathleen Doheny HealthDay Reporter ... diet of fast food might hurt your child in the ... fast food in fifth grade lagged behind by eighth grade, ... than 8,500 U.S. students. "The largest effects were found ... said study leader Kelly Purtell, assistant professor of human sciences ...
    (Date:12/24/2014)... 2014 (HealthDay News) -- Longer and colder body cooling does ... brain damage from a lack of oxygen, a new study ... with this condition -- called hypoxic ischemic encephalopathy -- can ... Celsius (92.3 Fahrenheit) for 72 hours, experts say. Research ... of animals, so this study examined if the same would ...
    Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2
    ... shows young donors experience a lower rate of adverse reactions ... , LAKE ZURICH, Ill., June 23 Fenwal Inc. ... Richard J. Benjamin, M.D., Ph.D., chief medical officer of the ... relative safety of automated two-unit red cell procedures and manual ...
    ... Healthcare, Inc. (PDHI) launches the ConXus Profile Third-Party Health ... merge historical data from third-party HRAs with data collected ... may be reluctant to switch their current HRA data ... health information accumulated over time. PDHI has developed ...
    ... say , TUESDAY, June 23 (HealthDay News) -- Women ... developing brain lesions, a new study has found. , Whether ... cognition, however, remains unknown, the researchers added. , "Migraine used ... occurred, but these data suggest that there may be tissue ...
    ... to maintain a healthy weight, , TUESDAY, June 23 (HealthDay ... increases the risk for pancreatic cancer, and obesity in middle ... new study finds. , Pancreatic cancer is the fourth leading ... United States. As the number of people who are overweight ...
    ... ... threaten financial and emotional health -- and your life, says cancer survivor Jo ... of health insurers. She thought the healthcare system might have changed since she ... serious condition. Godfrey knows she is not alone, and she is ...
    ... ... needs of our nation,s over-the-road drivers and will showcase their efforts at The Great West ... ... Lifeclinic International, Inc., the world,s leading manufacturer and distributor of automated blood pressure monitors ...
    Cached Medicine News:Health News:Fenwal to Host Webinar on the Safety of 2-Unit Red Cell Collections From Young Donors 2Health News:Fenwal to Host Webinar on the Safety of 2-Unit Red Cell Collections From Young Donors 3Health News:PDHI Launches ConXus Profile Third-Party Health Risk Assessment Data-Load Process 2Health News:Migraine With Aura May Lead to Brain Lesions 2Health News:Migraine With Aura May Lead to Brain Lesions 3Health News:Obesity While Young Boosts Pancreatic Cancer Risk 2Health News:Obesity While Young Boosts Pancreatic Cancer Risk 3Health News:Insurance May Be Hazardous to Your Health: "They Figured It Was Cheaper to Kill Me" 2Health News:Insurance May Be Hazardous to Your Health: "They Figured It Was Cheaper to Kill Me" 3Health News:Insurance May Be Hazardous to Your Health: "They Figured It Was Cheaper to Kill Me" 4Health News:Lifeclinic Teams Up With Trucking Industry to Promote Health and Wellness to Over-the-Road Professionals 2Health News:Lifeclinic Teams Up With Trucking Industry to Promote Health and Wellness to Over-the-Road Professionals 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: